Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program

  • Posted on 14 September, 2023
    Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
    Read more

    Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

    • Posted on 11 August, 2023
      Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead...
      Read more

      Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise

      • Posted on 27 April, 2023
        MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...
        Read more